Skip to main content

Kintor OK'd to Start US Trial of Androgen Receptor Antagonist for COVID-19

Suzhou 's Kintor Pharma reported the US FDA approved a Phase III trial of proxalutamide as a treatment for male COVID-19 outpatients. Proxalutamide is Kintor's novel androgen receptor (AR) antagonist that is currently being tested as a prostate and breast cancer therapy in Phase I-III trials in China and the  US . Kintor says proxalutamide may limit the expression of ACE-2 and TMPRSS2, which plays a role in allowing SARS-CoV-2 to bind and enter host cells in the lung. In a clinical trial, proxalutamide significantly lowered the SARS viral load over the control. More details.... Stock Symbol: (HK: 9939) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.